Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disorder characterized by non-neoplastic bone formation in soft tissues. It usually follows blunt trauma and bleeding in the deep soft tissues.
Biomarker and diagnostic research for myositis ossificans has been reported in the published literature.
9 clinical trials registered, 4 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3, 4 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05039515](https://clinicaltrials.gov/study/NCT05039515) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
PHASE2 |
Clementia Pharmaceuticals Inc. |
UNKNOWN |
[NCT05090891](https://clinicaltrials.gov/study/NCT05090891) | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | PHASE2 | Incyte Corporation | RECRUITING |
[NCT04307953](https://clinicaltrials.gov/study/NCT04307953) | Saracatinib Trial TO Prevent FOP | PHASE2 | Amsterdam UMC, location VUmc | ACTIVE_NOT_RECRUITING |
[NCT06724562](https://clinicaltrials.gov/study/NCT06724562) | IL1 Inhibition in FOP | — | University of California, San Francisco | RECRUITING |
[NCT05394116](https://clinicaltrials.gov/study/NCT05394116) | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | PHASE3 | Regeneron Pharmaceuticals | ACTIVE_NOT_RECRUITING |
132 publications have been identified in PubMed for myositis ossificans. Research spans Case Report / Case Series (52%), Basic Science / Preclinical (15%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 69 | 52% |
Laboratory research | 20 | 15% |
Research summaries | 14 | 11% |
Clinical study results | 8 | 6% |
New treatment approaches | 8 | 6% |
Testing and diagnosis research | 5 | 4% |
Disease patterns and progression | 5 | 4% |
Other research | 3 | 2% |
Street M (2026). [PMID: 40249624](https://pubmed.ncbi.nlm.nih.gov/40249624/). *Mil Med*. [Case Report / Case Series]
Hanson LR (2026). [PMID: 41672263](https://pubmed.ncbi.nlm.nih.gov/41672263/). *Bone*. [Basic Science / Preclinical]
Al Karam TM (2026). [PMID: 41970064](https://pubmed.ncbi.nlm.nih.gov/41970064/). *Cureus*. [Case Report / Case Series]
Nakken ER (2026). [PMID: 41538463](https://pubmed.ncbi.nlm.nih.gov/41538463/). *JBJS Case Connect*. [Case Report / Case Series]
Kada S (2026). [PMID: 41646603](https://pubmed.ncbi.nlm.nih.gov/41646603/). *Cureus*. [Case Report / Case Series]
Acikgoz NB (2026). [PMID: 42068419](https://pubmed.ncbi.nlm.nih.gov/42068419/). *Eur J Pediatr*. [Diagnostic / Biomarker]
Ye T (2026). [PMID: 41918028](https://pubmed.ncbi.nlm.nih.gov/41918028/). *J Med Case Rep*. [Case Report / Case Series]
Chavhan AS (2026). [PMID: 41566805](https://pubmed.ncbi.nlm.nih.gov/41566805/). *Indian journal of pathology & microbiology*. [Case Report / Case Series]
Ozaki S (2026). [PMID: 41606656](https://pubmed.ncbi.nlm.nih.gov/41606656/). *J Med Case Rep*. [Case Report / Case Series]
Meng ZQ (2026). [PMID: 41956746](https://pubmed.ncbi.nlm.nih.gov/41956746/). *Zhonghua Bing Li Xue Za Zhi*. [Case Report / Case Series]
AI-curated news mentioning myositis ossificans
Updated Jun 6, 2026
A case report details a rare overlap syndrome of pembrolizumab-induced myocarditis, myositis, and myasthenia gravis in a patient with endometrial carcinoma. The report highlights concurrent hepatitis and thyroiditis, emphasizing the complexity of immune-related adverse events.
A recent study highlights the complexities of diagnosing and treating calcinosis cutis and delayed-onset myositis in a patient with suspected localized scleroderma. This case underscores the need for careful evaluation in rare disease presentations.